J Virol, April 1998, p. 2832-2845, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Specific Interactions between Retrovirus Env
and Gag Proteins in Rat Neurons
Katarzyna
Weclewicz,1
Maria
Ekström,2
Krister
Kristensson,1 and
Henrik
Garoff2,*
Department of Neuroscience, Karolinska
Institute, S-171 77 Stockholm,1 and
Department of Biosciences at Novum, S-141 57 Huddinge,2 Sweden
Received 21 August 1997/Accepted 17 December 1997
 |
ABSTRACT |
In this work we have studied the intracellular localization
properties of the Gag and Env proteins of Moloney murine leukemia virus
(MLV) and human immunodeficiency virus (HIV) in dorsal root ganglion
(DRG) neurons of rat. These neurons form thick bundles of axons, which
facilitates protein localization studies by immunofluorescence analyses. When such neuron cultures were infected with recombinant Semliki Forest virus particles carrying the gag genes of
either retrovirus, the expressed Gag proteins were localized to both the somatic and the axonal regions of the DRG neurons. In contrast, the
Env proteins were confined only to the somatic region. When the Gag and
Env proteins were coexpressed, the Gag proteins were also excluded from
the axons. This effect of the Env proteins was shown to be dependent on
the concentration of the Gag proteins in the neuron and also to be
specific for homologous pairs of retrovirus proteins. Therefore, the
results suggest that there are specific interactions between the Env
and the Gag proteins of MLV and HIV in the DRG neurons.
 |
INTRODUCTION |
All enveloped viruses are equipped
with transmembrane proteins, called envelope (Env) proteins or spikes,
on their surface. These proteins enable the particles to bind to host
cell receptors and, further, to penetrate into the cell cytoplasm by a
virus membrane-host membrane fusion event. The most reasonable
explanation of how the envelope proteins become incorporated into the
viral membrane is that there are specific interactions between the
internal (cytoplasmic) core or capsid structure of the virus and the
cytoplasmic domains (tails) of the viral membrane proteins. If these
interactions drive the budding process of the virus, only
entry-competent particles which contain spike proteins will be
produced. While this budding model has been verified for several
alphaviruses (e.g., Semliki Forest virus [SFV], Sindbis virus, and
Ross River virus) (5, 33, 36) and hepadnaviruses (e.g.,
hepatitis B virus) (1a, 2, 9), it does not hold true for
retroviruses. Several studies have shown that intracellular expression
of the cytoplasmic Gag precursor protein alone results in its membrane
binding, core formation, and budding into the medium of the host cells
(7, 13, 15, 26, 35). These results have confirmed some early reports on the existence of helper-dependent retrovirus particles that
lack the Env proteins (25, 28). This ability of the Gag precursor protein raises an important question about how Env proteins are incorporated into the retroviral envelope. One possibility is that
the Env proteins are incorporated by specific Env-Gag interactions that
are functionally uncoupled from the budding reaction. According to
another model, there is no interaction between the Env and Gag proteins
at all, but the Env proteins end up in the particle passively after
being localized to that region of the cell membrane where the
Gag-driven budding takes place. Therefore, a key question concerning
the incorporation mechanism of Env is whether there is an Env-Gag
interaction or not.
Several recent studies suggest that such an interaction exists, at
least in the case of lentiviruses. First, Owens et al. (23)
showed that human immunodeficiency virus (HIV) Env will restrict HIV
Gag budding to the basolateral (BL) plasma membrane (PM) domain of the
polarized epithelial cell line MDCK. When Gag was expressed separately,
budding occurred from both the BL and the apical PM domains. The most
reasonable explanation for this phenomenon is that Gag proteins
interact with Env proteins, which are known to be targeted to the BL
PM. Second, studies with both HIV and simian immunodeficiency virus
have shown that certain mutations in the NH2-terminal
domain (MA) of Gag will block incorporation of Env into the viral
envelope during budding (10, 14). However, Env proteins with
tail deletions were not blocked. These data suggested that Env proteins
with intact tails can enter the envelope only by interactions with Gag
but that if the tail has been deleted, then Env can be incorporated
unspecifically. Third, Cosson (6) used an in vitro assay to
demonstrate a specific binding between HIV MA and the tail of HIV Env.
Thus, it is very likely that HIV incorporates the Env proteins into its
envelope by an interaction with the Gag proteins during budding. In the
case of other retroviruses, the existence of an Env-Gag interaction is
still an open question.
In the present work we have studied this interaction in Moloney murine
leukemia virus (MLV) and HIV by monitoring the localization properties
of their Gag and Env proteins in primary neuron cultures from rat
dorsal root ganglia (DRG). The corresponding retroviral genes were
introduced into DRG neurons by infection with recombinant SFV
particles. We show that the Gag proteins localize to both the somatic
and axonal regions of the DRG cells when expressed separately. However,
when coexpressed with the homologous Env protein, but not with the
heterologous one, the Gag protein localization becomes restricted to
the somatic region of the cell, the domain that is used by the
retroviral Env proteins. Thus, these results suggest that the Env and
Gag proteins of MLV and HIV can interact with each other in a specific
way in the DRG neurons.
 |
MATERIALS AND METHODS |
Primary cell culture.
DRG neurons were obtained from embryos
of pregnant Sprague-Dawley rats (B&K, Stockholm, Sweden) taken on day
15 to 18 of gestation. The cultures were prepared as described by
Sotelo et al. (31). Briefly, DRG were dissociated by several
passages through a constricted Pasteur pipette, and the cells were
seeded on collagen-coated (Collagen Corporation, Palo Alto, Calif.)
glass coverslips (G. Menzel, Braunschweig, Germany) attached to the
bottom of sterile plastic petri dishes (Costar, Cambridge, Mass.). The
culture medium consisted of minimum essential medium (MEM) supplemented
with 10% fetal bovine serum, 10% horse serum, 2% chicken embryo
extract, gentamicin sulfate (15 µg/ml), and L-glutamine
(200 mM) (all obtained from Gibco, Paisley, Scotland) and glucose (6 mg/ml) and nerve growth factor (1 ng/ml) (Sigma Chemical Co., St.
Louis, Mo.). The medium was changed three times a week. The cultures
were exposed for 48 h to a cytostatic agent, cytosine arabinoside
(3 µg/ml) (Sigma Chemical Co.), after 4 to 5 days to inhibit
proliferation of nonneuronal cells. For further incubation the bovine
serum was omitted from the medium. The primary DRG cultures consisted of differentiated neurons and a population of nonneuronal cells, predominantly fibroblasts and Schwann cells. Neurons constituted approximately 30 to 50% of all cells in such cultures. The choices of
medium supplements, inclusion or exclusion of neurotrophic factors, and
adhesive properties of the underlying substrate were based on
observation of the survival and differentiation of the sensory neurons.
The proportion, presence, or absence of the various substances was
found to be critical for an optimal microenvironment.
Hippocampal cells were prepared from rat embryos after 18 days of
gestation, generally as described before (27). The
hippocampi were dissected, trypsinized (0.1% trypsin [Gibco] for 15 min at 37°C), and dissociated by several passages through a
constricted Pasteur pipette. Cell suspensions were seeded on glass
coverslips coated with poly-L-lysine hydrobromide (Sigma
Chemical Co.) and placed in petri dishes. The culture medium,
Dulbecco's MEM-Nutrient Mix F12 (Gibco) and 10% fetal bovine serum,
was supplemented with glucose (1.2 mg/ml), 20 nM progesterone, 100 µM
putrescine, and 30 nM selenium dioxide (all from Sigma Chemical Co.)
and bovine insulin (5 µg/ml) and human transferrin (100 µg/ml)
(both from Gibco). Penicillin and streptomycin (Gibco) were added to
final concentrations of 20 U/ml and 20 µg/ml, respectively.
After 14 days in culture, DRG and hippocampal cells were incubated with
recombinant SFV diluted in MEM (total volume, 600 µl/petri dish).
After 1 h of incubation at 37°C, culture medium was added for a
total of 2 ml/petri dish. The cultures were sampled at 6 and 16 h
postinfection, which were found to be optimal infection times as
estimated from the protein expression level and preservation of
neurons. Morphological cytotoxic effects became evident after 24 h, when neuronal perikarya swelled, processes retracted, and, finally,
the cells detached from the coverslips.
BHK-21 cell culture.
Baby hamster kidney (BHK-21) cells,
obtained from the American Type Culture Collection, were grown in
Glasgow MEM (BHK-21) and supplemented with 10% tryptose phosphate
broth, 5% fetal bovine serum, 20 mM HEPES, and 2 mM glutamine (all
obtained from Gibco). Cells were washed once with phosphate-buffered
saline (PBS) (without Ca2+ and Mg2+) (Gibco),
trypsinized with 1× trypsin-EDTA (0.5 and 0.2 mg/ml, respectively)
(Gibco) in PBS (without Ca2+ and Mg2+), and
subcultivated 1:5 every second day. Cells were incubated at 37°C in
5% CO2-95% O2.
Plasmids.
High-expression-level plasmids were (i) SFV-C-hTR,
which encodes the human transferrin receptor (hTR) (19);
(ii) SFV-C-hTR
2, which encodes a variant hTR in which most of its
cytoplasmic domain is deleted (32); (iii)
SFV-C-gagMLV, which encodes the Gag precursor protein of
MLV (32); and (iv) SFV-C-gagHIV, which encodes
the Gag precursor of HIV (16a). Low-expression-level plasmids were (i) SFV-1-gagMLV, which encodes the Gag
precursor of MLV (32); (ii) SFV-1-envMLV, which
encodes the Env precursor of MLV (32); (iii)
SFV-1-gagHIV, which encodes the Gag precursor of HIV
(16a); and (iv) SFV-1-envHIV, which encodes the
Env precursor of HIV (24). In addition, the SFV Helper 1 plasmid was used (19).
Antibodies.
The following primary antibodies were used: (i)
anti-HIV Env antibody P4/D10, a monoclonal antibody (MAb) which
recognizes GP120 (kindly provided by B. Wahren, Karolinska Institute,
Stockholm, Sweden); (ii) anti-HIV Gag antibody RL4.72.1.1, a MAb which
recognizes p24/p55 (Aalton, Dublin, Ireland); (iii) anti-MLV antibody
HC185, a polyclonal pig antiserum which recognizes whole MLV (Quality Biotech Inc.); (iv) anti-MLV Gag, a rabbit antiserum which recognizes p30 (kindly provided by G. Smith, Institute for Molecular Virology, GSF, Münich, Germany); (v) anti-MLV Env MAb 500, a MAb which recognizes gp70 (kindly provided by B. W. Chesebro, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Mont.); (vi)
anti-hTR antibody OKT9, a MAb which recognize hTR (prepared by T. Ebel
by using the corresponding hybridoma cell line, which was obtained from
the American Type Culture Collection); and (vii) anti-MAP2, a MAb which
recognizes the microtubule-associated protein 2 (MAP2) (Sigma Chemical
Co.).
Secondary antibodies were (i) fluorescein isothiocyanate
(FITC)-conjugated rabbit anti-mouse F(ab)2 fragment of
immunoglobulin (IgG) (Dakopatts A/S, Copenhagen, Denmark), (ii)
FITC-conjugated swine anti-rabbit IgG (Dakopatts), and (iii)
tetramethylrhodamine isothiocyanate-conjugated rabbit anti-mouse IgG
(Dakopatts).
Preparation of recombinant SFV.
Expression plasmids were
used for transcription of recombinant SFV RNA in vitro as described
before (19). Recombinant SFV particles were produced by
cotransfecting 107 BHK-21 cells with recombinant SFV and
Helper 1 RNA, also as described before (19). Yields of
recombinant virus varied between 107 and 108
infectious particles per ml. Recombinant viruses were stored in small
aliquots at
80°C.
Immunofluorescence analyses.
Cells grown on glass coverslips
were washed twice with Dulbecco's PBS (PBS with Mg2+ and
Ca2+) (Gibco) and then fixed either in cold methanol
(
20°C) for 5 to 6 min or in 4% formaldehyde at room temperature
for 30 min. For immunolabelling with the MAbs, the cells were
preincubated with 2% normal rabbit serum (Dakopatts) and 0.3% Triton
X-100 (Eastman Kodak Company, Rochester, N.Y.) for 5 min at room
temperature. The cultures were then incubated for 1 h at room
temperature with one of the MAbs diluted in 2% normal rabbit serum and
0.3% Triton X-100. After being rinsed in Dulbecco's PBS, the cells
were incubated with FITC-conjugated rabbit anti-mouse
F(ab)2 fragment of IgG (Dakopatts) diluted 1:15 in
Dulbecco's PBS with 2% normal rat serum (Dakopatts) for 30 min at
37°C. After being rinsed in distilled water, the cultures were
mounted in glycerol. For labelling with the rabbit anti-MLV Gag
hyperimmune serum, the cells were preincubated with 2% normal swine
serum (Dakopatts) and 0.3% Triton X-100 for 5 min at room temperature
followed by the anti-MLV Gag antiserum diluted in 2% normal swine
serum and 0.3% Triton X-100 for 1 h at room temperature. After
being rinsed, the cells were incubated with FITC-conjugated swine
anti-rabbit IgG (Dakopatts) diluted 1:15 in Dulbecco's PBS containing
2% normal rat serum for 30 min at 37°C. For double labelling the
cells were first incubated with the anti-MLV Gag antiserum, washed, and
then incubated with the anti-HIV Env MAb diluted in 2% normal horse
serum (Vector Laboratories, Burlingame, Calif.). After being rinsed,
the cells were incubated with FITC-conjugated swine anti-rabbit IgG,
followed by incubation with tetramethylrhodamine
isothiocyanate-conjugated rabbit anti-mouse IgG (Dakopatts) diluted
1:30 in 2% normal rat serum for 30 min at 37°C, and mounted.
Metabolic labelling of cells and preparation of cell
lysates.
Neuron and BHK-21 cell cultures were used for labelling
with [35S]methionine 6 h after infection. Culture
media were replaced with methionine-free MEM (Gibco). After 30 min at
37°C, media were replaced with 500 µl of the same methionine-free
medium containing 50 µCi of [35S]methionine (Amersham
International plc, Bucks, England), and cells were incubated at 37°C
for 30 min. After the 30-min pulse, cells were washed twice with MEM
(Gibco) containing a 10-fold excess of cold methionine (Gibco) and then
incubated in the same medium for 15 or 120 min at 37°C (chase). After
the 120-min chase, media were collected and clarified by centrifugation
in an Eppendorf centrifuge for 5 min at 5,000 rpm and 4°C. After
pulse-chasing of HIV-infected cells, the medium was removed and cells
were washed with cold PBS and lysed with 300 µl of Nonidet P-40
(NP-40) lysis buffer. This contained 1% NP-40, 50 mM Tris-HCl (pH
7.6), 150 mM NaCl, 2 mM EDTA, 10 µg of phenylmethylsulfonyl fluoride
per ml, and 20 mM N-ethylmaleimide. Nuclei were removed from
cell lysates by centrifugation in an Eppendorf centrifuge for 5 min at
6,000 rpm and 4°C. After pulse-chasing of MLV-infected cells, the
medium was removed and cells were washed with PBS and lysed with 300 µl of sodium dodecyl sulfate (SDS) lysis buffer. This contained 1%
SDS, 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 2 mM EDTA, 10 µg of
phenylmethylsulfonylfluoride per ml, and 20 mM
N-ethylmaleimide. SDS lysis was done at room temperature.
The SDS lysate was passed five times through a 20 G1 1/2 9 by 40 needle, heated to 95°C for 2 min, and centrifuged in an Eppendorf
centrifuge for 2 min at 14,000 rpm. The supernatant was transferred to
a fresh tube.
Analyses of virus particles.
Virus particles were harvested
from clarified 120-min chase medium by pelleting them through a 10%
sucrose cushion in a Beckman JA 18.1 rotor at 17,000 rpm for 2 h
at 4°C. Pelleted particles were taken up into SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) sample buffer, heated for 5 min at 95°C,
and analyzed by SDS-PAGE.
Immunoprecipitation.
MLV Gag and Env precursors were
immunoprecipitated from SDS cell lysates with the anti-MLV antiserum.
HIV precursors were immunoprecipitated from NP-40 cell lysates with
anti-HIV Env and anti-HIV Gag antibodies. Aliquots of SDS lysates (100 µl) were diluted with 900 µl of NET buffer, which contained 1%
NP-40, 50 mM Tris-HCl (pH 8.0), 400 mM NaCl, 5 mM EDTA (pH 8.0), and
0.02% NaN3, and mixed with the antibody and 40 µl of
protein A-Sepharose (Pharmacia Biotech, Uppsala, Sweden) (50%
[vol/vol] in 10 mM Tris-HCl, pH 7.5). The samples were then rotated
end over end for 16 h at 4°C. Pellets were washed twice with a
solution containing 0.2% NP-40, 10 mM Tris-HCl (pH 7.5), 150 mM NaCl,
and 2 mM EDTA; twice with a solution containing 0.2% NP-40, 10 mM
Tris-HCl (pH 7.5), 500 mM NaCl, and 2 mM EDTA; and finally once with a
solution containing 10 mM Tris-HCl (pH 7.5). The immunoprecipitation in
NP-40 cell lysates was done as previously described (34).
SDS-PAGE.
Immunoprecipitates and pelleted virus particles
were taken up into 40 µl of SDS-gel sample buffer, which contained
200 mM Tris-HCl (pH 8.8), 20% glycerol, 5 mM EDTA, 0.02% bromphenol
blue, 1 mM methionine, 4% SDS, and 50 mM dithiothreitol. The sample mixture was heated for 5 min at 95°C before being analyzed on a 10 or
15% gel. After electrophoresis, gels were processed for autoradiography (30). Quantitation of radioactivity of the
protein in gel bands was done with a Fuji phosphorimager (type FUJIX
BAS 2000 TR). For calculation of protein ratios, the PSL values of corresponding proteins were normalized for the methionine content of
respective protein.
Electron microscopic analyses.
Hippocampal and DRG cultures
were infected with SFV-C-gagHIV or SFV-C-gagMLV
recombinant virus particles. At 6 and 16 h postinfection the cultures were fixed in 1% glutaraldehyde-PBS, postfixed in
OsO4, and embedded in LX112 (Ladd, Burlington, Vt.). For
orientation, semithin sections stained with toluidine blue were used.
For electron microscopy, ultrathin sections were cut and stained with
uranyl acetate and lead citrate.
 |
RESULTS |
Analyses of protein targeting in dorsal root ganglia neurons with
recombinant SFV.
It has recently been shown that rat hippocampus
neurons can be infected with recombinant SFV carrying a foreign gene
and that these cells retain their typical morphological features for
several hours (21, 22). This has facilitated gene expression
experiments with these cells, for instance, for the purpose of studying
the mechanisms of axonal and dendritic protein transport. However, analyses of the axonal distribution of a protein in hippocampus neurons
are sometimes difficult because the latter extensions have such small
diameters. Therefore, we investigated whether DRG cultures could be
used for similar studies (31). The DRG neuron differs
considerably in morphology from the hippocampus neuron (8,
17). DRG neurons form very thick bundles of axons, while
dendritic extensions are completely lacking. A typical DRG neuron is
shown in Fig. 1a. The compact cell body
(the somatic region) and the thick bundle of axons are clearly visible.
We first analyzed the distribution of the endogenous MAP2 in these neurons by using immunofluorescence after membrane permeabilization. This marker protein is known to be present in free and
tubulin-associated forms in the somatodendritic domain of hippocampus
neurons but to be excluded from their axon extensions (3,
20). The staining of the cells in our DRG culture showed a
corresponding polarity: the cell body was positive, whereas the axon
bundle was negative (Fig. 1b). For comparison, MAP2 staining in a
hippocampus neuron is also shown (Fig. 1c). In this case, clear somatic
and dendritic staining was observed.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 1.
Immunofluorescence analyses of MAP2 in nerve cells. DRG
neurons (a and b) and a hippocampus neuron (c) were stained with
anti-MAP2 antibodies and examined by fluorescence (b and c) and
Nomarski (a) microscopy. Arrow, axon bundle of the DRG neuron.
Magnification, ×375.
|
|
Next we studied the distribution of hTR in DRG neurons. This marker
protein was expressed by infecting the neurons with SFV-C-hTR recombinant particles. Rat TR has earlier been shown to be confined to
the dendrites of hippocampus neurons (4). Consistent with these earlier findings, staining of the infected DRG cultures with an
hTR-specific MAb (which does not react with the endogenous receptor)
showed clear staining of the cell body, whereas the thick axon bundle
remained unstained (Fig. 2a and b). It
should be noted that this restricted localization of hTR was maintained although the SFV-C-based vector is known to express very high levels of
this receptor molecule (29). As a control we also stained
hippocampus neurons and observed strong somatodendritic staining (Fig.
2e). The distribution of the hTR between the internal (endosomal) and
surface pools was not examined. However, we know that a fraction of hTR
is also stained in nonpermeabilized hippocampus and DRG neurons (data
not shown).

View larger version (109K):
[in this window]
[in a new window]
|
FIG. 2.
Immunofluorescence analyses of hTR in nerve cells. DRG
neurons (a to d) and a hippocampus neuron (e) were infected with
SFV-C-hTR (a, b, and e) or SFV-C-hTR 2 (c and d), incubated for
6 h, and stained with anti-hTR antibodies that do not react with
rat TR. Panels b and d are Nomarski images of the stained cells in
panels a and c, respectively. Note the restricted localization of hTR
to the soma of the DRG neuron in panel a, whereas the corresponding
cytoplasmic tail deletion variant localizes to the axon bundle as well
(c). Magnification, ×375.
|
|
In order to test the importance of the cytoplasmic tail of hTR for the
localization behavior of TR, we infected the DRG neurons with a vector
expressing a cytoplasmic tail deletion variant of hTR (SFV-C-hTR
2).
This corresponds to a deletion variant which has been used before to
show that the tail contains a BL targeting signal of this protein in
epithelial cells (18). The results of this localization
analyses are exemplified by the immunofluorescence staining in Fig. 2c.
It is evident not only that the hTR
2 is present in the somatic
region but also that strong staining is seen in the axon bundle. This
finding was consistent for all infected and stained DRG neurons of the
culture. These results suggest that there is somatic targeting
information in the cytoplasmic tail of hTR. We conclude that the DRG
cultures can be used with advantage to study signal-mediated protein
targeting in neurons.
SFV recombinants expressing retrovirus proteins.
Six different
SFV recombinants were used to express the MLV and HIV Gag and Env
proteins. SFV-C-gagMLV was used for high-level expression
of the MLV Gag protein, whereas SFV-1-gagMLV and
SFV-1-envMLV were used to express the MLV proteins at a
comparatively lower level. SFV-C-gagHIV,
SFV-1-gagHIV, and SFV-1-envHIV were the
corresponding vectors for the expression of HIV proteins. It should be
noted that the infectivity and RNA replication of SFV-1 and SFV-C
vectors are equal; only the mRNA translatability differs. The
SFV-C-based vectors contain a translation-enhancing RNA segment in the
SFV capsid (C)-coding part of the subgenomic mRNA which is used for
heterologous gene expression in this vector (29). We also
constructed SFV-C-env vectors for high-level expression of the Env
proteins. However, high-level synthesis of the MLV and HIV Env proteins
was associated with severe folding problems in the endoplasmic
reticulum, and these vectors therefore could not be used
(1).
Synthesis of Gag and Env proteins of MLV and HIV in DRG
neurons.
DRG cultures were infected with the various SFV-1-based
recombinant viruses and analyzed for protein expression by SDS-PAGE. The results are shown in Fig. 3. The
cells were labelled with [35S]methionine for 30 min and
then chased as indicated before the preparation of cell and medium
samples. Figure 3a, lanes 5 to 7, shows that 65-kDa Gag precursors of
MLV are produced in the SFV-1-gagMLV-infected ganglion
neurons and also are released as particles into the medium. This is
very similar to their behavior in BHK cell cultures (Fig. 3a, lanes 2 to 4), which has been reported before (32). Note the
efficient shutdown of host protein synthesis when the SFV expression
system is used. This facilitates quantitative and qualitative analyses
of the expressed proteins directly from cell extracts. Note also that
much less protein is expressed in DRG than in BHK cultures. The major
reason is that there are fewer cells in the DRG culture. Figure 3b,
lanes 5 and 6, shows the synthesis of the Env precursor protein of MLV
in SFV-1-envMLV-infected cells. This is the same size (80 kDa) as the corresponding product in BHK cells (Fig. 3b, lanes 2 and
3). After the 120-min chase, the transmembrane cleavage product Pr15E
can be detected. There is also some degradation of the Env precursors
in the DRG neurons during the 120-min chase.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 3.
SDS-gel analyses of retroviral proteins expressed in DRG
neurons and BHK-21 cells. DRG neuron and BHK-21 cell cultures were
infected with recombinant SFV carrying the genes for Gag and Env
precursors, incubated, pulse-labelled, chased (15 and 120 min), and
processed (without immunoprecipitation if not indicated) for analyses
on 10% gels. SFV-infected cells were used as a control. Pelletable
material from medium samples was also analyzed. L and M, cell lysate
and medium samples. (a, b, c, and d) Analyses of MLV Gag precursor, MLV
Env precursor, HIV Gag precursor, and HIV Env precursor, respectively.
The MLV-specific Pr65gag, Pr80env, and Pr15E
protein bands and the HIV-specific Pr55gag and
Pr160env protein bands, as well as the SFV-specific E1, E2,
and C protein bands, are indicated.
|
|
Figure 3c and d show corresponding analyses of cells infected with
SFV-1-gagHIV and SFV-1-envHIV. It is evident
that the Gag and Env products of the nerve cells (Fig. 3c and d, lanes
5 and 6) migrated similarly to the 55-kDa Gag and the 160-kDa Env
precursors that were produced in infected BHK cell cultures (Fig. 3c
and d, lanes 2 and 3), which has been previously observed (16a,
24). In the present experiment, no Gag particles could be
detected in the medium. The release of such particles is much less
efficient in the case of HIV than with MLV (16a). We
conclude that authentic MLV and HIV proteins were produced in the
infected DRG cultures.
Morphological analyses of Gag particles in
SFV-1-gagMLV- and SFV-1-gagHIV-infected nerve
cells.
An electron micrograph of an
SFV-1-gagMLV-infected DRG neuron is shown in Fig.
4a. Several free and budding MLV Gag
particles are present. Most particles were spherical, with a diameter
of approximately 130 nm. In Fig. 5a to c,
infected hippocampus neurons are shown for comparison. In these cells,
budding and accumulation of MLV Gag particles were also found at or
near synaptic membranes (Fig. 5b and c). Corresponding analyses of
SFV-1-gagHIV-infected DRG and hippocampus neurons are shown
in Fig. 4b and 5d. Note the difference between HIV and MLV Gag particle
morphology: the MLV particle appear to have a double-layered structure
below the viral envelope, whereas the HIV particle has only a single layer. These are typical features for these two different retroviruses (11, 12).

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 4.
Electron microscopic analyses of Gag particle budding in
DRG neurons. Cultures with DRG neurons were infected with recombinant
SFV carrying the genes for MLV Gag (a) and HIV Gag (b), incubated for
6 h, and processed for electron microscopic analyses. Bars, 200 nm.
|
|

View larger version (192K):
[in this window]
[in a new window]
|
FIG. 5.
Electron microscopic analyses of Gag particle budding in
hippocampus neurons. Cultures with hippocampus neurons were infected
with recombinant SFV carrying the genes for MLV Gag (a to c) and HIV
Gag (d), incubated for 16 h, and processed for electron
microscopic analyses. In panels b and c, MLV Gag particles are shown to
bud at dendrite-like processes. Note the morphological difference
between the membrane-associated layers of the MLV and HIV particles.
Bars, 200 nm.
|
|
Localization of Env and Gag precursors in neurons.
The
distribution of the MLV and HIV proteins in the infected neurons was
studied by immunofluorescence analyses of permeabilized cells. We first
compared the staining patterns of separately expressed Gag and Env
proteins in infected hippocampus and DRG neurons. Figure
6 shows photomicrographs of infected
hippocampus neurons. The Gag and Env proteins of both retroviruses are
localized in the entire somatodendritic region of the hippocampus
neurons. The thin axon extensions of these cells are not easily
detected, but two possible ones which are positive for HIV and MLV Gag
precursors, respectively, are indicated in Fig. 6b and d. These are
thin nontapering extensions lacking branches at acute angles. Figures
7 and 8a (upper panels) show corresponding micrographs of infected DRG neurons.
In these, the Gag precursors of both retroviruses are shown to be
distributed in the cell body as well as in the thick, clearly visible
axon bundle. Figure 8b shows a larger view of a DRG culture that has
been infected with SFV-1-gagHIV and stained for the HIV Gag
protein. However, it should be noted that there was an apparent
difference between the two kinds of Gag proteins in their efficiency in
reaching the axons. While MLV Gag proteins entered axons in virtually
all DRG neurons which were infected with SFV-1-gagMLV, the
HIV Gag proteins entered the axon extensions in only about 65% of the
SFV-1-gagHIV-infected neurons (Table
1). In addition, some infected ganglion neurons showed HIV Gag protein staining only in the
proximal part of the axon bundle. In contrast to the Gag proteins, the
Env proteins of both viruses were found to be restricted to the cell
body. This is shown for MLV Env in Fig. 7 (upper panel) and for HIV Env
in Fig. 8a (upper panel). It should be noted that these analyses do not
indicate how much of the Env precursors is present at the cell surface.
A major fraction of the Env precursors might actually reside in
intracellular membranes of the cell body. However, this possibility
does not interfere with our main conclusions from the results of the
coexpression experiments described below.

View larger version (111K):
[in this window]
[in a new window]
|
FIG. 6.
Immunofluorescence analyses of MLV and HIV Gag and Env
precursor proteins in hippocampus neurons. Cultures with hippocampus
neurons were infected with recombinant SFV carrying the genes for HIV
Env (a), HIV Gag (b), MLV Env (c), and MLV Gag (panel d). The cultures
were incubated for 6 h and stained with anti-HIV Env (a), anti-HIV
Gag (b), anti-MLV Env (c), and anti-MLV Gag (d). Arrows, putative axon
extensions. Magnification, ×375.
|
|

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 7.
Immunofluorescence analyses of MLV Gag and Env precursor
proteins in DRG neurons. Several parallel DRG cultures were infected
with recombinant SFV carrying the genes for MLV Gag and Env either
separately or together, as indicated to the left. After incubation, the
cultures were stained with anti-MLV Gag ( gag) or anti-MLV Env ( env) antibodies, as indicated at the top. The ratios given to the left
indicate the ratio of Gag to Env proteins as determined by quantitation
of radioactive bands in gel analyses of samples from parallel cultures.
Nomarski views are also indicated. Magnification, ×380.
|
|

View larger version (55K):
[in this window]
[in a new window]

View larger version (95K):
[in this window]
[in a new window]
|
FIG. 8.
Immunofluorescence analyses of HIV Gag and Env
precursors in DRG neurons. (a) Analyses were done as described in the
legend to Fig. 7 for the corresponding MLV proteins. gag, staining
with anti-HIV Gag antiserum; env, staining with anti-HIV Env
antibodies. Magnification, ×380. (b) A larger view of a DRG culture
that has been infected with SFV-1-gagHIV and stained with
anti-HIV Gag antibodies. Magnification, ×225. (c) Left panel,
immunofluorescence analysis of HIV Env in a nonpermealized DRG neuron;
right panel, corresponding Nomarski view.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
MLV and HIV Gag protein distributions in DRG neurons when
expressed separately or together with their homologous
envelope precursor
|
|
Coexpression of homologous Env and Gag proteins restricts Gag
protein localization to the somatic region of DRG neurons.
Analyses of the Gag precursor distribution in DRG neurons coinfected
with SFV-1-gagMLV and SFV-1-envMLV revealed a
location of the Gag protein which was restricted to the somatic region
of the neuron (Fig. 7, middle panel). Of 200 Gag-positive cells, 95%
showed this distribution (Table 1). Although double-immunofluorescence
analyses were not possible in this experiment, the very frequent
soma-specific Gag localization observed in the coinfected cells
suggests an efficient coexpression of the two viral proteins in the
neurons.
Thus, these results indicate that the MLV Env proteins, which are
inserted into the membranes of the somatic part of the DRG, can
interact with the Gag proteins and thereby restrict the latter to the
somatic domain of the neuron. If this model is correct, then one would
expect that the overexpression of Gag relative to Env proteins should
allow the Gag proteins to enter into the axons. We tested this by using
the SFV-C-gagMLV vector, which expresses about 10 times
more Gag protein than SFV-1-gagMLV (29). When
ganglion neurons were coinfected with SFV-1-envMLV and
SFV-C-gagMLV recombinant viruses, the immunofluorescence
analyses showed that the Gag proteins reached the axon in 95% of
Gag-positive cells (Fig. 7 [lower panel] and Table 1). The ratio of
the Env and Gag protein concentrations in the neurons was estimated by
SDS-PAGE analyses of corresponding proteins in the lysate of another
ganglion cell culture which had been coinfected in parallel and then
pulse-labelled (Fig. 9a). After
quantitation of the radioactivities in Gag and Env protein bands and
normalization of these values for the number of methionine residues for
the respective proteins, we found that there were about nine times more
Gag than Env proteins in the cell sample (Table 1). This should be
compared with an approximately 1:1 ratio of Gag to Env proteins that we
found in those cultures which had been coinfected with the two SFV-1
vectors and which showed the soma-specific Gag protein distribution
(Table 1).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 9.
SDS-gel analyses of retroviral proteins coexpressed in
DRG neurons and BHK-21 cells. (a) Analyses of MLV, Gag, and Env
proteins coexpressed in same DRG culture at a 9:1 molar ratio. Lane L,
lysate sample; lane , sample obtained by immunoprecipitation of the
lysate with anti-MLV serum. (b) Analyses of HIV Gag and Env proteins
coexpressed in the same DRG culture at a 1:1 molar ratio. Lane gag,
sample obtained by immunoprecipitation of the lysate with anti-HIV Gag
antibodies; lane env, sample obtained by immunoprecipitation of the
lysate with anti-HIV Env antibodies.
|
|
When DRG neurons were coinfected with SFV-1-gagHIV and
SFV-1-envHIV recombinant viruses and analyzed for Gag and
Env protein distribution by immunofluorescence, we observed the same
Gag distribution as described above for MLV proteins. With this
procedure the Gag precursors were localized in the somatic region and
not in the axons as was the case when the Gag protein had been
separately expressed (Fig. 8a, middle panel). Upon examination of
several hundred Gag-positive cells, we found only 5% of the neurons
with Gag proteins in the axon extension (Table 1). The Env
protein-directed effect seemed to be dependent on the concentration of
the HIV precursor molecules, because when we used the
SFV-C-gagHIV vector to overexpress the Gag protein, the
latter was found in the axon extensions (Fig. 8a, lower panel). In this
case about 65% of the Gag-positive cells displayed Gag proteins in the
axons (Table 1). Quantitation of Env and Gag proteins from SDS gel analyses of labelled lysates from
SFV-1-gagHIV/SFV-1-envHIV- and
SFV-C-gagHIV/SFV-1-envHIV-infected neurons and
subsequent calculation of relative concentrations of Gag and Env
proteins showed that these were about 1:1 and 9:1, respectively (Fig.
9b; Table 1). Therefore, we conclude that the exclusion of Gag
localization in axons depends on the relative concentrations of the Gag
and Env proteins in the neuron. This clearly supports the hypothesis of
direct binding of the Gag protein to the Env protein.
Coexpression of heterologous Gag-Env protein pairs cannot restrict
Gag expression to the somatic region of DRG neurons.
In order to
analyze the specificity of the proposed Gag-Env interaction, we
performed a series of coexpression experiments using vector
combinations which directed the expression of heterologous pairs of Gag
and Env proteins. We first analyzed whether the HIV Env protein could
influence the distribution of the MLV Gag protein by using DRG neurons
coinfected with SFV-1-envHIV and SFV-1-gagMLV
recombinant viruses. As previous expression studies using the homologous combinations have demonstrated that the Env protein-directed somatodendritic restriction in Gag localization requires a Gag-to-Env precursor concentration ratio of close to 1 or lower, we tried to vary
the ratio of the recombinant particles in the mixtures used for the
infection of the neuron cultures accordingly. This was somewhat
difficult with the combination of SFV-1-gagMLV and
SFV-1-envHIV, since the HIV Env protein was expressed at a
considerably lower level than the corresponding MLV protein. However,
reasonable precursor ratios were produced (Table
2). By using the Gag-specific polyclonal
antibody and the Env-specific MAb, it was possible to make double
stainings and study the Env and Gag protein distribution specifically
in neurons that were coexpressing the two proteins. The results showed
that the MLV Gag proteins reached the axon extensions in all
double-stained cells, whereas the HIV Env proteins were confined to the
somatic region only (Table 2). Representative stainings are shown in
Fig. 10 (upper panel).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 10.
Immunofluorescence analyses of heterologous retrovirus
precursor combinations in DRG neurons. (Top) Analyses with cells
infected with recombinant SFV carrying genes for MLV Gag and HIV Env.
The Gag/Env protein ratio was 1:1. Anti-MLV Gag antiserum and anti-HIV
Env antibodies were used for staining. (Bottom) DRG cells infected with
recombinant SFV carrying the genes for HIV Gag and MLV Env. The Gag/Env
protein ratio was 1:7. Staining was with anti-HIV Gag antibodies.
Magnification, ×370.
|
|
Similar studies were also done with several combinations of
SFV-1-gagHIV and SFV-1-envMLV recombinant
viruses (Table 2). Unfortunately, we could not use double stainings in
these experiments. However, as the MLV Env protein expression was
always severalfold higher than that of HIV Gag protein, we assume that
a substantial fraction of the HIV Gag-positive neurons were also
expressing the MLV Env protein (Table 2). The staining with the
anti-HIV Gag antibody showed that 60 to 70% of the Gag-positive cells
displayed Gag proteins in both the soma and axon (Fig. 10 [lower
panel]; Table 2). This is about the same frequency that we observed in
the experiments in which the HIV Gag protein was expressed separately
(Table 1). Thus, these results indicate that the MLV Env protein was
not able to influence the distribution of the HIV Gag protein in the DRG neurons. We conclude from these experiments that the Env protein is
able to restrict only its homologous Gag protein to the somatic region
of the neuron. This suggests that the Gag protein-Env protein interaction causing this effect is specific for homologous proteins.
 |
DISCUSSION |
We have used an SFV vector-DRG cell system to study the
Env-Gag protein interaction of two retroviruses, MLV and HIV. Our major
finding is that the Env proteins of these viruses are able to restrict
the distribution of the homologous Gag proteins to the somatic region
of DRG neurons. If expressed separately, the Gag proteins of both
viruses will also distribute into the axon bundles of the neurons. This
Env protein-directed restriction of Gag protein distribution was shown
to be dependent on the relative concentrations of the two proteins in
the neuron. If the Gag protein was expressed in excess over the Env
protein, the Gag protein was able to enter into the axon. These results
support a mechanism for Env protein-directed Gag localization that is
based on an interaction between the two viral proteins. Furthermore, we
showed that the Gag protein localization was not restricted by
heterologous Env proteins. The latter result indicates that the
observed effect is based on a specific interaction between homologous
Gag and Env proteins in DRG neurons. Thus, our results confirm earlier data on the existence of a Gag-Env interaction in HIV and, most importantly, suggest that such an interaction also takes place in MLV.
This supports a model for Env incorporation into MLV particles that is
based on an Env-Gag interaction. Previously, the sole support for an
Env-Gag interaction in MLV has been the observation that MLV variants
with certain tail mutations in the Env protein were defective in Env
incorporation into virions (15, 16). However, in those
studies it remained unclear whether the mutant Env proteins were
actually defective in Gag binding or whether they simply were unable to
reach the Gag budding sites at the PM.
It will still be important to corroborate our findings in DRG neurons
with direct in vitro binding studies. Further, the Env-Gag interactions
of other retroviruses should also be studied. The most suitable
approach is probably to use both in vitro binding and polarized cell
assays. A full understanding of the Gag-Env interaction in the
lentiviruses, MLV, and other retroviruses will, however, require a
detailed structural analysis of the Env tail-Gag complexes.
 |
ACKNOWLEDGMENTS |
This study was supported by grants from the Swedish Natural
Science Research Council (no. B-AA/BU 09353-311), the Cancer Foundation (no. 96 4165), the Human Capital and Mobility Network (no. CHRX-CT 94-0496), the Stanley Foundation Research Awards Program, and the
Swedish Medical Research Council (no. 4480).
We thank Ingrid Jusinsky (Clinical Research Center, Huddinge, Sweden)
for excellent preparation of the electron microscopy material, Ingrid
Sigurdson for typing, and Mathilda Sjöberg for critical reading
of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biosciences at Novum, Karolinska Institutet, S-141 57 Huddinge, Sweden. Phone: 46-8-608-91-25. Fax: 46-8-608-92-80. E-mail:
henrik.garoff{at}cbt.ki.se.
 |
REFERENCES |
| 1.
| Andersson, H., M. Ekström, and H. Garoff. Unpublished observations.
|
| 1a.
|
Bruss, V., and D. Ganem.
1991.
The role of envelope proteins in hepatitis B virus assembly.
Proc. Natl. Acad. Sci. USA
88:1059-1063[Abstract/Free Full Text].
|
| 2.
|
Bruss, V., and K. Vieluf.
1995.
Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis.
J. Virol.
69:6652-6657[Abstract].
|
| 3.
|
Caceres, A.,
G. A. Banker,
O. Steward,
L. Binder, and M. Payne.
1984.
MAP2 is localized to dendrites of hippocampal neurons which develop in culture.
Dev. Brain Res.
13:314-318.
|
| 4.
|
Cameron, P. L.,
T. C. Südhof,
R. Jahn, and P. De Camilli.
1991.
Colocalization of synaptophysin with transferrin receptors: implications for synaptic vesicle biogenesis.
J. Cell Biol.
115:151-164[Abstract/Free Full Text].
|
| 5.
|
Cheng, R. H.,
R. J. Kuhn,
N. H. Olson,
M. G. Rossmann,
H.-K. Choi,
T. J. Smith, and T. S. Baker.
1995.
Nucleocapsid and glycoprotein organization in an enveloped virus.
Cell
80:621-630[Medline].
|
| 6.
|
Cosson, P.
1996.
Direct interaction between the envelope and matrix proteins of HIV-1.
EMBO J.
15:5783-5788[Medline].
|
| 7.
|
Delchambre, M.,
D. Gheysen,
D. Thines,
C. Thiriart,
E. Jacobs,
E. Verdin,
M. Horth,
A. Burny, and F. Bex.
1989.
The GAG precursor of simian immunodeficiency virus assembles into virus-like particles.
EMBO J.
8:2653-2660[Medline].
|
| 8.
|
Dotti, C. G., and K. Simons.
1990.
Polarized sorting of viral glycoproteins to the axon and dendrites of hippocampal neurons in culture.
Cell
62:63-72[Medline].
|
| 9.
|
Dyson, M. R., and K. Murray.
1995.
Selection of peptide inhibitors of interactions involved in complex protein assemblies: association of the core and surface antigens of hepatitis B virus.
Proc. Natl. Acad. Sci. USA
92:2194-2198[Abstract/Free Full Text].
|
| 10.
|
Freed, E. O., and M. A. Martin.
1995.
Virus incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix.
J. Virol.
69:1984-1989[Abstract].
|
| 11.
|
Gelderblom, H. R.
1991.
Assembly and morphology of HIV: potential effect of structure on viral function.
AIDS
5:617-638[Medline].
|
| 12.
|
Gelderblom, H. R.,
P. G. Bauer,
M. Özel,
P. Höglund,
M. Niedrig,
H. Renz,
B. Morath,
P. Lundquist,
Å. Nilsson,
J. Mattow,
C. Grund, and G. Pauli.
1992.
Morphogenesis and morphology of human immunodeficiency virus, p. 33-54. In
R. C. Aloia, et al. (ed.), Membrane interactions of HIV.
Wiley-Liss, Inc., New York, N.Y.
|
| 13.
|
Gheysen, D.,
E. Jacobs,
F. de Foresta,
C. Thiriart,
M. Francotte,
D. Thines, and M. De Wilde.
1989.
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected cells.
Cell
59:103-112[Medline].
|
| 14.
|
González, S. A.,
A. Burny, and J. L. Affranchino.
1996.
Identification of domains in the simian immunodeficiency virus matrix protein essential for assembly and envelope glycoprotein incorporation.
J. Virol.
70:6384-6389[Abstract].
|
| 15.
|
Granowitz, C.,
J. Colicelli, and S. P. Goff.
1991.
Analysis of mutations in the envelope gene of Moloney murine leukemia virus: separation of infectivity from superinfection resistance.
Virology
183:545-554[Medline].
|
| 16.
|
Gray, K. D., and M. J. Roth.
1993.
Mutational analysis of the envelope gene of Moloney murine leukemia virus.
J. Virol.
67:3489-3496[Abstract/Free Full Text].
|
| 16a.
| Hewson, R., and H. Garoff. Unpublished data.
|
| 17.
|
Inczedy-Marcsek, M.,
L. Hsu, and E. Lindner.
1993.
An analysis of dorsal root ganglia differentiation using three tissue culture systems..
Vitro Cell. Dev. Biol. 29A:661-670
.
|
| 18.
|
Kundu, A., and D. P. Nayak.
1994.
Analysis of the signals for polarized transport of influenza virus (A/WSN/33) neuraminidase and human transferrin receptor, type II transmembrane proteins.
J. Virol.
68:1812-1818[Abstract/Free Full Text].
|
| 19.
|
Liljeström, P., and H. Garoff.
1991.
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.
Bio/Technology
9:1356-1361[Medline].
|
| 20.
|
Matus, A.,
R. Bernhardt,
R. Bodmer, and D. Alaimo.
1986.
Microtubule-associated protein 2 and tubulin are differently distributed in the dendrites of developing neurons.
Neuroscience
17:371-389[Medline].
|
| 21.
|
Olkkonen, V. M.,
P. Dupree,
K. Simons,
P. Liljeström, and H. Garoff.
1994.
Expression of exogenous proteins in mammalian cells with the Semliki Forest virus vector.
Methods Cell Biol.
43:43-53.
|
| 22.
|
Olkkonen, V. M.,
P. Liljeström,
H. Garoff,
K. Simons, and C. G. Dotti.
1993.
Expression of heterologous proteins in cultured rat hippocampal neurons using the Semliki Forest virus vector.
J. Neurosci. Res.
35:445-451[Medline].
|
| 23.
|
Owens, R. J.,
J. W. Dubay,
E. Hunter, and R. W. Compans.
1991.
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.
Proc. Natl. Acad. Sci. USA
88:3987-3991[Abstract/Free Full Text].
|
| 24.
|
Paul, N.,
M. Marsh,
J. A. McKeating,
T. F. Schulz,
P. Liljeström,
H. Garoff, and R. A. Weiss.
1993.
Expression of HIV-1 envelope glycoprotein by Semliki Forest virus.
AIDS Res. Hum. Retroviruses
9:963-970[Medline].
|
| 25.
|
Pinter, A., and E. deHarven.
1979.
Protein composition of a defective murine sarcoma virus particle possessing the enveloped type-A morphology.
Virology
99:103-110[Medline].
|
| 26.
|
Rhee, S. S.,
H. Hui, and E. Hunter.
1990.
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane.
J. Virol.
64:3844-3852[Abstract/Free Full Text].
|
| 27.
|
Rothman, S.
1984.
Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death.
J. Neurosci.
4:1884-1891[Abstract].
|
| 28.
|
Scheele, C. M., and H. Hanafusa.
1971.
Proteins of helper-dependent RSV.
Virology
45:401-410[Medline].
|
| 29.
|
Sjöberg, M.,
M. Suomalainen, and H. Garoff.
1994.
A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene.
Bio/Technology
12:1127-1131[Medline].
|
| 30.
|
Smyth, J.,
M. Suomalainen, and H. Garoff.
1997.
Efficient multiplication of a Semliki Forest virus chimera containing Sindbis virus spikes.
J. Virol.
71:818-823[Abstract].
|
| 31.
|
Sotelo, S.,
C. J. Gibbs,
D. C. Gajdusek,
B. H. Toh, and M. Wurth.
1980.
Method for preparing cultures of neurons: cytochemical and immunochemical studies.
Proc. Natl. Acad. Sci. USA
77:653-657[Abstract/Free Full Text].
|
| 32.
|
Suomalainen, M., and H. Garoff.
1994.
Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus.
J. Virol.
68:4879-4889[Abstract/Free Full Text].
|
| 33.
|
Suomalainen, M.,
P. Liljeström, and H. Garoff.
1992.
Spike protein-nucleocapsid interactions drive the budding of alphaviruses.
J. Virol.
66:4737-4747[Abstract/Free Full Text].
|
| 34.
|
Wahlberg, J. M.,
W. A. Boere, and H. Garoff.
1989.
The heterodimeric association between the membrane proteins of Semliki Forest virus changes its sensitivity to mildly acidic pH during virus maturation.
J. Virol.
63:4991-4997[Abstract/Free Full Text].
|
| 35.
|
Wills, J. W.,
R. C. Craven, and J. A. Achacoso.
1989.
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells.
J. Virol.
63:4331-4343[Abstract/Free Full Text].
|
| 36.
|
Zhao, H.,
B. Lindqvist,
H. Garoff,
C.-H. von Bonsdorff, and P. Liljeström.
1994.
A tyrosine-based motif in the cytoplasmic domain of the alphavirus envelope protein is essential for budding.
EMBO J.
13:4204-4211[Medline].
|
J Virol, April 1998, p. 2832-2845, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.